Gene test may guide kidney cancer therapy choice

NCT ID NCT05361720

Recruiting now Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immunotherapy plus a targeted therapy pill (nivolumab plus cabozantinib), based on their tumor's genetic profile. The goal is to see if this personalized approach leads to better tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabozantinib, Ipilimumab, Nivolumab
What this could lead to: If successful, this could show that genetic testing helps doctors pick the most effective treatment for each patient with advanced kidney cancer, potentially improving outcomes.
What could go wrong: This is an early phase 2 trial with only 54 participants, so results may not apply to everyone. The genetic testing approach may not improve response rates as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CLEAR CELL RENAL CELL CARCINOMA METASTATIC CLEAR CELL RENAL CELL CARCINOMA STAGE III RENAL CELL CANCER AJCC V8 STAGE IV RENAL CELL CANCER AJCC V8

Contacts and locations

Locations

Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
University Hospitals Seidman Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of Texas, Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.